More than 1,000+ patients treated since FDA approval in 2020.
Get more information about PEMAZYRE, including how it works and how it was studied.
Get more information about PEMAZYRE, including how it works and how it was studied.
PEMAZYRE is a prescription medicine that is used to treat adults with bile duct cancer (cholangiocarcinoma) that has spread or cannot be removed by surgery:
Your healthcare provider will test your cancer for a certain type of abnormal FGFR2 gene and make sure that PEMAZYRE is right for you.
It is not known if PEMAZYRE is safe and effective in children.
PEMAZYRE is approved based on tumor response and duration of response. There are ongoing studies to show whether PEMAZYRE can improve survival or symptoms.
Before you take PEMAZYRE (pemigatinib), tell your healthcare provider about all of your medical conditions, including if you:
Females who can become pregnant:
Males with female partners who can become pregnant:
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
What are the possible side effects of PEMAZYRE?
PEMAZYRE may cause serious side effects, including:
The most common side effects of PEMAZYRE for cholangiocarcinoma include:
These are not all the possible side effects of PEMAZYRE. For more information, ask your healthcare provider or pharmacist.
Call your doctor for medical advice about side effects.
You may report side effects to FDA at
Keep PEMAZYRE and all medicines out of the reach of children.
General information about the safe and effective use of PEMAZYRE.
Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use PEMAZYRE for a condition for which it is not prescribed. Do not give PEMAZYRE to other people, even if they have the same symptoms you have. It may harm them. If you would like more information, talk with your healthcare provider. You can ask your pharmacist or healthcare provider for information that is written for healthcare professionals.
Please see the Full Prescribing Information, including Patient Information, which includes a more complete discussion of the risks associated with PEMAZYRE.
PEMAZYRE is a prescription medicine that is used to treat adults with bile duct cancer (cholangiocarcinoma) that has spread or cannot be removed by surgery:
Your healthcare provider will test your cancer for a certain type of abnormal FGFR2 gene and make sure that PEMAZYRE is right for you.
It is not known if PEMAZYRE is safe and effective in children.
PEMAZYRE is approved based on tumor response and duration of response. There are ongoing studies to show whether PEMAZYRE can improve survival or symptoms.
Before you take PEMAZYRE (pemigatinib), tell your healthcare provider about all of your medical conditions, including if you:
Females who can become pregnant:
Males with female partners who can become pregnant:
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
What are the possible side effects of PEMAZYRE?
PEMAZYRE may cause serious side effects, including:
The most common side effects of PEMAZYRE for cholangiocarcinoma include:
These are not all the possible side effects of PEMAZYRE. For more information, ask your healthcare provider or pharmacist.
Call your doctor for medical advice about side effects.
You may report side effects to FDA at
Keep PEMAZYRE and all medicines out of the reach of children.
General information about the safe and effective use of PEMAZYRE.
Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use PEMAZYRE for a condition for which it is not prescribed. Do not give PEMAZYRE to other people, even if they have the same symptoms you have. It may harm them. If you would like more information, talk with your healthcare provider. You can ask your pharmacist or healthcare provider for information that is written for healthcare professionals.
Please see the Full Prescribing Information, including Patient Information, which includes a more complete discussion of the risks associated with PEMAZYRE.